

**August 15,2024**

**High-Cost Specialty Drug (BIO) Amtagvi effective date changed to 08/01/2024 from initial effective date of 10/01/2024**

The High-Cost Specialty Drug (BIO) Amtagvi has been approved for an effective date of 08/01/2024.

**Amtagvi** (lifileucel) is approved to treat unresectable or metastatic melanoma for adults previously treated with a PD-1 blocking antibody, and, if the *BRAF*V600 mutation was positive, a BRAF inhibitor with or without a MEK inhibitor.